Mono acetyl Canagliflozin

Mono acetyl Canagliflozin is a structurally modified derivative of the antidiabetic agent Canagliflozin, featuring an acetyl group appended to one hydroxyl substituent of the glucopyranoside moiety. This modification introduces an acetoxy functionality adjacent to the parent compound’s 4-chlorobenzoyl-triazole-sulfonamide core, preserving the sulfonamide and triazole heterocycles critical for SGLT2 inhibition. The acetylation selectively masks a primary hydroxyl group, altering solubility and metabolic stability while maintaining structural similarity to the active pharmaceutical ingredient. This compound arises as a synthetic byproduct during API manufacturing processes involving acetylation conditions. It serves as a reference standard for HPLC-based quantification of acetylated impurities in Canagliflozin formulations.